La vendita allo scoperto per Tidal ETF Trust II YieldMax TSLA Option Income Strategy ETF dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Tidal ETF Trust II YieldMax TSLA Option Income Strategy ETF. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Tidal ETF Trust II YieldMax TSLA Option Income Strategy ETF (ARCA:TSLY), Report sulle vendite allo scoperto

The Fund is an actively managed exchange-traded fund (ETF) that seeks current income while maintaining the opportunity for exposure to the share price (i.e., the price returns) of the common stock of Tesla, Inc. (TSLA), subject to a limit on potential investment gains. The Fund will seek to employ its investment strategy as it relates to TSLA regardless of whether there are periods adverse market, economic, or other conditions and will not seek to take temporary defensive positions during such periods. As further described below, the Fund uses a synthetic covered call strategy to provide income and exposure to the share price returns of TSLA, subject to a limit on potential investment gains as a result of the nature of the options strategy it employs.

First American Government Obligations Fund

YieldMax TSLA Option Income Strategy ETF

Tidal ETF Trust II YieldMax TSLA Option Income Strategy ETF

Analysts' ratings for Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) over the last quarter vary from bullish to bearish, as provided by 11 analysts.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $190.82, a high estimate of $255.00, and a low estimate of $115.00. This current average has decreased by 10.94% from the previous average price target of $214.27. 
<img src="https://www.benzinga.com/files/images/story/2025/1749729668_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Biogen by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Salim Syed</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$169.00</td>
<td>$207.00</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$175.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$205.00</td>
<td>$217.00</td>
</tr>
<tr>
<td>Sumant Kulkarni</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$220.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$187.00</td>
<td>$241.00</td>
</tr>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$255.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$199.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$115.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$197.00</td>
<td>$219.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$225.00</td>
<td>$221.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$152.00</td>
<td>$157.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Biogen. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Biogen compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Biogen's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Biogen's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/BIIB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Biogen analyst ratings.</a>
<h2>About Biogen</h2>
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
<h3>Key Indicators: Biogen's Financial Health</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Biogen's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 6.13%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Biogen's net margin is impressive, surpassing industry averages. With a net margin of 9.89%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Biogen's ROE stands out, surpassing industry averages. With an impressive ROE of 1.43%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Biogen's ROA stands out, surpassing industry averages. With an impressive ROA of 0.86%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Biogen's debt-to-equity ratio is below the industry average at 0.39, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

BIIB

Demystifying Biogen: Insights From 11 Analyst Reviews

8 analysts have shared their evaluations of Dave (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Dave, presenting an average target of $200.12, a high estimate of $250.00, and a low estimate of $125.00. Witnessing a positive shift, the current average has risen by 32.03% from the previous average price target of $151.57.
<img src="https://www.benzinga.com/files/images/story/2025/1749729657_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of Dave's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Announces</td>
<td>Outperform</td>
<td>$250.00</td>
<td>-</td>
</tr>
<tr>
<td>Hal Goetsch</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$239.00</td>
<td>$206.00</td>
</tr>
<tr>
<td>Mark Palmer</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$229.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Devin Ryan</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$200.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Jacob Stephan</td>
<td>Lake Street</td>
<td>Raises</td>
<td>Buy</td>
<td>$177.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Mark Palmer</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$202.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Joseph Vafi</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$179.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Devin Ryan</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$125.00</td>
<td>$135.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Dave. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Dave compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Dave's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Dave's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DAVE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Dave analyst ratings.</a>
<h2>All You Need to Know About Dave</h2>
Dave Inc is a financial services company. It is engaged in offering banking app that offers its customers banking, financial insights, overdraft protection, building credit and finding side gigs.
<h3>Dave: A Financial Overview</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Positive Revenue Trend: Examining Dave's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 46.65% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.
Net Margin: Dave's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 26.68%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Dave's ROE excels beyond industry benchmarks, reaching 15.06%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Dave's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 9.37% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.38, Dave adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DAVE

Analyst Expectations For Dave's Future

In the last three months, 9 analysts have published ratings on Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>), offering a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Fabrinet, revealing an average target of $243.89, a high estimate of $290.00, and a low estimate of $176.00. Experiencing a 1.48% decline, the current average is now lower than the previous average price target of $247.56. 
<img src="https://www.benzinga.com/files/images/story/2025/1749729646_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Fabrinet. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Genovese</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$290.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>George Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$234.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Samik Chatterjee</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$235.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Ryan Koontz</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$280.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Mike Genovese</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$250.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Mike Genovese</td>
<td>Rosenblatt</td>
<td>Lowers</td>
<td>Buy</td>
<td>$230.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Samik Chatterjee</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$220.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Dave Kang</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$176.00</td>
<td>$178.00</td>
</tr>
<tr>
<td>Ryan Koontz</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$280.00</td>
<td>$280.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Fabrinet. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Fabrinet compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Fabrinet's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Fabrinet's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/FN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Fabrinet analyst ratings.</a>
<h2>About Fabrinet</h2>
Fabrinet provides advanced optical packaging and precision optical, electro-mechanical, and electronic manufacturing services to original equipment manufacturers of complex products, such as optical communication components, modules and sub-systems, industrial lasers, automotive components, medical devices, and sensors. The company offers a broad range of advanced optical and electro-mechanical capabilities across the entire manufacturing process, including process design and engineering, supply chain management, manufacturing, complex printed circuit board assembly, advanced packaging, integration, final assembly, and testing. The company generates the majority of its revenue from North America and Asia-Pacific, with the rest from Europe.
<h3>Financial Milestones: Fabrinet's Journey</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Positive Revenue Trend: Examining Fabrinet's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 19.17% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Fabrinet's net margin excels beyond industry benchmarks, reaching 9.32%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Fabrinet's ROE excels beyond industry benchmarks, reaching 4.34%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Fabrinet's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.15% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.0, Fabrinet adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Fabrinet's Future

Rocket Lab Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) announced on Wednesday it has successfully completed a milestone launch for a <a href="https://www.benzinga.com/pressreleases/25/06/b45889628/rocket-lab-successfully-launches-second-mission-for-iqps-in-rapid-25-day-turnaround">recurring customer from Japan</a>.
The California-based space company completed its 66th successful mission of its Electron rocket, delivering a synthetic aperture radar satellite into orbit for Institute for Q-shu Pioneers of Space, Inc. (iQPS).
This launch, dubbed "The Mountain God Guards," occurred on June 11 at 15:31 UTC from Rocket Lab's Launch Complex 1 in Mahia, New Zealand.
Also Read:<a href="https://www.benzinga.com/trading-ideas/technicals/25/06/45864329/this-direct-beneficiary-of-trump-musk-feud-rockets-500-in-1-year-more-fuel-left" target="_blank" rel="noreferrer noopener"> This &#8216;Direct Beneficiary&#8217; Of Trump-Musk Feud Rockets 500%+ In 1 Year &#8211; More Fuel Left?</a>
This marked the fourth deployment Rocket Lab has executed for iQPS, underscoring its reliability and precision in supporting constellation development.
The newly launched satellite, QPS-SAR-11, nicknamed YAMATSUMI-I after the Japanese mountain deity, is now part of a growing network designed to deliver high-resolution Earth observation data.
With this latest deployment, Rocket Lab has now launched half of iQPS's planned satellite fleet.
Notably, the company achieved two successful missions for iQPS within just 25 days, demonstrating its rapid turnaround capability in the small launch sector.
"The Electron team has delivered another flawless launch and satellite deployment for iQPS, for the second time in 25 days – an outstanding display of the reliability and agility that makes Electron the leader in dedicated small launch," said Sir Peter Beck, Rocket Lab's founder and CEO.
"We are truly pleased to see our satellites being placed into orbit one after another, marking significant progress toward building our satellite constellation," said Dr. Shunsuke Onishi, CEO of iQPS.
He added that three more dedicated launches are on the schedule for later this year, with additional missions slated for 2026.
This mission was Rocket Lab's eighth Electron mission of 2025 and its 66th launch overall. Another Electron launch is expected in the coming days from the same New Zealand facility.
Price Action: RKLB shares are trading lower by 2.19% to $26.76 at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/45899174/boeing-dreamliner-carrying-over-200-passengers-crashes-shortly-after-takeoff-near-indias-ahmedabad-ba-stock-falls-over-5-in-thursday-pre-market" target="_blank" rel="noreferrer noopener">Boeing Dreamliner Carrying Over 200 Passengers Crashes Shortly After Takeoff Near India&#8217;s Ahmedabad: BA Stock Falls Over 7% In Thursday Pre-Market (UPDATED)</a></li>
</ul>
Photo by Emagnetic via Shutterstock

Equities

News

Markets

Movers

General

RKLB

Rocket Lab Launches Fourth Mission For Japan's iQPS

Telsey Advisory Group analyst Dana Telsey maintains Oxford Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXM#NYSE">OXM</a>) with a Market Perform and maintains $52 price target.

Price Target

Telsey Advisory Group Maintains Market Perform on Oxford Industries, Maintains $52 Price Target

Alithya Group (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ALYA#TSX">ALYA</a>) reported quarterly earnings of $0.12 per share which beat the analyst consensus estimate of $0.05 by 140 percent. This is a 100 percent increase over earnings of $0.06 per share from the same period last year. The company reported quarterly sales of $125.33 million which beat the analyst consensus estimate of $119.80 million by 4.62 percent. This is a 3.97 percent increase over sales of $120.54 million the same period last year.

Earnings

Earnings Beats

TSX:ALYA

Alithya Group Q4 Adj. EPS $0.12 Beats $0.05 Estimate, Sales $125.33M Beat $119.80M Estimate

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/06/11/final-trades-qxo-evercore-charles-schwab-and-the-xle.html">Halftime Report Final Trades</a>,&#8221; Joseph M. Terranova, Senior Managing Director for Virtus Investment Partners, named The Charles Schwab Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) as his final trade.
Supporting his view, Redburn Atlantic analyst Charles Bendit, on June 9, upgraded Charles Schwab from Sell to Neutral and raised the price target from $65 to $82.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Stephen Weiss, Chief Investment Officer and Managing Partner of Short Hills Capital Partners, named QXO, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NYSE">QXO</a>) <a href="https://www.benzinga.com/quote/QXO">as his final trade</a>.
As per the recent news, QXO, on May 20, announced it launched a dual public offering of common stock and depositary shares representing series B convertible preferred stock.
Shannon Saccocia, CFA, Chief Investment Officer of NB Private Wealth, picked The Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) despite oil prices remaining pretty range-bound.  
Odyssey Capital Advisors Chief Investment Officer Jason Snipe said he likes Evercore Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVR#NYSE">EVR</a>), as M&amp;A cycle and deregulation are coming back into vogue.
Lending support to his choice, Evercore, on April 30, reported better-than-expected first-quarter financial results. 
Evercore posted adjusted earnings of $3.49 per share, beating market estimates of $1.71 per share. The company's quarterly sales came in $699.9 million versus expectations of $652.92 million.
Price Action:
<ul class="wp-block-list">
<li>QXO shares fell 1% to close at $19.95 on Wednesday.</li>
<li>The Energy Select Sector SPDR Fund gained 1.5% during the session.</li>
<li>Evercore rose 1.2% to close at $247.54 on Wednesday.</li>
<li>Charles Schwab shares gained 0.2% to settle at $88.40 during the session.</li>
</ul>
Check This Out: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45882911/top-2-consumer-stocks-that-may-plunge-in-june">Top 2 Consumer Stocks That May Plunge In June</a></li>
</ul>
Image: Shutterstock

Analyst Color

Long Ideas

Media

Trading Ideas

SCHW

Charles Schwab, QXO, Evercore And More: CNBC's 'Final Trades'

Rosenblatt analyst Chris Brendler maintains TeraWulf (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>) with a Buy and raises the price target from $4.5 to $6.

WULF

Rosenblatt Maintains Buy on TeraWulf, Raises Price Target to $6

Rosenblatt analyst Mike Genovese maintains Lumentum Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) with a Buy and maintains $105 price target.

LITE

Rosenblatt Maintains Buy on Lumentum Holdings, Maintains $105 Price Target

Rosenblatt analyst Mike Genovese maintains Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) with a Buy and raises the price target from $250 to $290.

Rosenblatt Maintains Buy on Fabrinet, Raises Price Target to $290

WIIM

CVAC

CureVac shares are trading higher after BioNTech announced it will acquire the company in an all-stock transaction.

Rosenblatt analyst Mike Genovese maintains Calix (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALX#NYSE">CALX</a>) with a Buy and raises the price target from $52 to $56.

CALX

Rosenblatt Maintains Buy on Calix, Raises Price Target to $56

Stock Split

SMX to Begin Trading On Reverse Split Adjusted Basis On Jun. 16

Spirit AeroSystems shares are trading lower in sympathy with Boeing following the Air India Dreamliner crash.

Anglogold Ashanti shares are trading higher after Roth Capital initiated coverage with a buy rating and a $52 price target.

PLRZ

Polyrizon shares are trading higher after the company reported preclinical results showing its Trap & Target formulation achieved targeted deposition in the upper nasal cavity.

NIVF

NewGen shares are trading higher after the company announced a planned $45 million investment in the UAE real estate market.

Boeing shares are trading lower after an Air India 787-8 Dreamliner crashed near the Ahmedabad airport.

AAOI

Applied Optoelectronics shares are trading higher after the company announced the first volume shipment of data center transceivers to a hyperscale customer.

Comments

Tidal ETF Trust II YieldMax TSLA Option Income Strategy ETF

Vendite allo scoperto

Tidal ETF Trust II YieldMax TSLA Option Income Strategy ETF (ARCA:TSLY), Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO